Cargando…
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to...
Autores principales: | Lopes, Natália Lôres, Campos, Diefrey Ribeiro, Machado, Marília Alves, Alves, Mariana Silva Revoredo, de Souza, Manuela Silva Gomes, da Veiga, Cristiano Chaves Pessoa, Merlo, Alexandre, Scott, Fábio Barbour, Fernandes, Julio Israel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506962/ https://www.ncbi.nlm.nih.gov/pubmed/31068210 http://dx.doi.org/10.1186/s12917-019-1893-x |
Ejemplares similares
-
Middle ear cholesteatoma in two cats diagnosed with the aid of video-otoscopy
por: Botelho, Cristiane Bazaga, et al.
Publicado: (2023) -
Fatal disseminated toxoplasmosis in a feline immunodeficiency virus‐positive cat receiving oclacitinib for feline atopic skin syndrome
por: Moore, Alexandra, et al.
Publicado: (2022) -
Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib
por: Ashton, Laura V, et al.
Publicado: (2020) -
Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib
por: Mwacalimba, Kennedy, et al.
Publicado: (2023) -
Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma
por: Ashton, Laura V., et al.
Publicado: (2023)